Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anavex Lf SC (AVXL)

Anavex Lf SC (AVXL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip?

Anavex Life Sciences (AVXL) stock crashed on March 25 after the company unexpectedly withdrew its marketing authorization application for blarcamesine in the European Union. 

The decision followed negative feedback from the European Medicines Agency (EMA), which indicated it would not issue a positive opinion for Alzheimer's treatment.

Fundamentals

See More
  • Market Capitalization, $K 253,921
  • Shares Outstanding, K 92,672
  • Annual Sales, $ 0 K
  • Annual Income, $ -46,380 K
  • EBIT $ -45 M
  • EBITDA $ -45 M
  • 60-Month Beta 1.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.96

Options Overview Details

View History
  • Implied Volatility 109.80% (-172.93%)
  • Historical Volatility 133.86%
  • IV Percentile 72%
  • IV Rank 11.26%
  • IV High 475.96% on 11/13/25
  • IV Low 63.34% on 05/27/25
  • Expected Move (DTE 22) 0.54 (18.82%)
  • Put/Call Vol Ratio 0.48
  • Today's Volume 492
  • Volume Avg (30-Day) 2,761
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 84,386
  • Open Int (30-Day) 68,904
  • Expected Range 2.35 to 3.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +46.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.61 +10.92%
on 03/25/26
5.18 -44.07%
on 03/04/26
-1.57 (-35.09%)
since 02/26/26
3-Month
2.61 +10.92%
on 03/25/26
5.36 -45.99%
on 01/22/26
-0.75 (-20.47%)
since 12/26/25
52-Week
2.61 +10.92%
on 03/25/26
13.99 -79.31%
on 07/24/25
-6.46 (-69.07%)
since 03/26/25

Most Recent Stories

More News
Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip?

Anavex shares crash as the EMA indicates it won’t issue a positive opinion on its candidate Alzheimer’s drug. Here’s why long-term investors may still consider loading up on AVXL stock today.

AVXL : 2.88 (+5.11%)
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 2.88 (+5.11%)
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease

New data show brain-volume preservation correlates with patient outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI 1 control...

AVXL : 2.88 (+5.11%)
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease

NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 2.88 (+5.11%)
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference

New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine ...

AVXL : 2.88 (+5.11%)
Anavex Life Sciences to Present at the Citizens Life Sciences Conference

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 2.88 (+5.11%)
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 2.88 (+5.11%)
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...

AVXL : 2.88 (+5.11%)
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

AVXL : 2.88 (+5.11%)
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update

Company to host a  webcast today at 8:30 am Eastern Time NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...

AVXL : 2.88 (+5.11%)

Business Summary

ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill...

See More

Key Turning Points

3rd Resistance Point 3.54
2nd Resistance Point 3.33
1st Resistance Point 3.03
Last Price 2.88
1st Support Level 2.53
2nd Support Level 2.32
3rd Support Level 2.02

See More

52-Week High 13.99
Fibonacci 61.8% 9.64
Fibonacci 50% 8.30
Fibonacci 38.2% 6.96
Last Price 2.88
52-Week Low 2.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.